CompletedPhase 2NCT03770273
Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis
Studying Indolent systemic mastocytosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Principal Investigator
- Hirsh D Komarow, M.D., M.DNational Institute of Allergy and Infectious Diseases (NIAID)
- Intervention
- sarilumab(biological)
- Enrollment
- 21 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2019 – 2023
Study locations (1)
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03770273 on ClinicalTrials.govOther trials for Indolent systemic mastocytosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07255638A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in GermanyBlueprint Medicines Corporation
- ACTIVE NOT RECRUITINGPHASE2NCT05186753(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic MastocytosisCogent Biosciences, Inc.
- RECRUITINGPHASE2, PHASE3NCT04910685(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic MastocytosisBlueprint Medicines Corporation
- RECRUITINGPHASE2NCT04655118Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic MastocytosisTelios Pharma, Inc.
- ACTIVE NOT RECRUITINGPHASE2NCT03731260(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic MastocytosisBlueprint Medicines Corporation